Apogee Therapeutics recently reported positive 16-week results from its APEX Phase 2 Part A trial, with APG777 meeting all primary and key secondary endpoints in moderate-to-severe atopic dermatitis ...

Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Multi-Center, ...

For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study ...

For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study published online July 15 in the American Journal of Clinical Dermatology. Andrew ...

Any vitamin D treatment in pregnancy may help prevent childhood asthma (1 study, 236 participants), and higher-dose vitamin D treatment in pregnancy likely helps prevent childhood wheeze (3 studies, ...

Patients with moderate to severe and severe alopecia areata have a greater burden of comorbid atopic dermatitis than those with mild alopecia areata.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Apogee plans to conduct Phase 2b trials in asthma and eosinophilic esophagitis (EoE) with trial designs informed by APEX Part B dose optimization as well as the Phase 1b results in asthma. Apogee ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

Get insights on Corvus Pharmaceuticals' Q2 2025 earnings call. Learn about soquelitinib's clinical progress, Phase II trial plans, and financial strategies.

Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...